BiomX Inc.

The Registrant could not complete the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 within the prescribed time period without unreasonable effort or expense which delay could not be eliminated by the Registrant without unreasonable effort and expense. Additional time is required to complete the preparation and review of the Registrant’s financial statements and related disclosures for the quarter, principally because (i) key internal accounting personnel of the Registrant have been unexpectedly unavailable due to a personal emergency, (ii) additional time is required to finalize the accounting for, and the disclosures relating to, the acquisitions of a controlling interest in Dr. Frucht Systems Ltd. and of ZorroNet Ltd. completed in April 2026, including the related purchase price allocations, fair value measurements, and related party matters, and (iii) the Registrant’s change in independent registered public accounting firm effective July 1, 2026 has required additional time for the Registrant’s new independent registered public accounting firm to complete its review procedures for the quarter. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, Registrant will file its Quarterly Report on Form 10-Q no later than the fifth calendar day following the prescribed due date. 2

The Registrant could not complete the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 within the prescribed time period due to the delay in obtaining and compiling information relating to significant transactions that were completed in the quarter and required to be included in the Company’s Form 10-Q, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, Registrant will file its Quarterly Report on Form 10-Q no later than the fifth calendar day following the prescribed due date. 2

The Registrant is unable to file the Form 10-Q in a timely manner because the Registrant was not able to timely complete its financial statements without unreasonable effort or expense, due to the Registrant’s recent completion of a merger with Adaptive Phage Therapeutics, Inc. (“APT”) and a concurrent investment (the “PIPE”), leading to the Registrant’s need to include the financial implications of the acquisition of APT and the PIPE that were closed on March 15, 2024 and to include APT’s financial results in the Registrant’s financial statements filed on Form 10-Q. The Registrant anticipates filing its Form 10-Q for the period ended March 31, 2024 on or before the fifth calendar day following the prescribed due date

of Form 10-K due to its inability to file a Proxy Statement for the Registrant’s annual meeting within 120 days after the end of the 2023 fiscal year. The Registrant anticipates filing its Form 10-K for the period ended December 31, 2023 on or before the fifteenth calendar day following the prescribed due date

The Registrant is unable to file the Form 10-Q for the quarter ended March 31, 2021 in a timely manner because the Registrant was not able to timely complete its financial statements without unreasonable effort or expense, due primarily to the reason described below. The Registrant is in the process of finalizing the accounting analysis of its outstanding common stock warrants that was undertaken in light of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies issued by the staff of the Securities and Exchange Commission on April 12, 2021. Although the analysis has not yet been finalized, the Registrant at this time does not expect that the accounting for its outstanding warrants will change as a result of this analysis. The Registrant also does not expect that its unaudited financial statements for the 2021 first quarter will include a significant change in results of operations from the corresponding period for the last fiscal year, as previously reported. The Registrant anticipates filing its Form 10-Q for the period ended March 31, 2021 within the five-day extension period